Nano-X Imaging’s Ties to NVIDIA Causes a Massive Surge in Stock Price

Photo of author
Written By Faith Boluwatife

February saw Nano-X Imaging (NASDAQ: NNOX), a promising medical imaging start-up, experience a staggering 105.1% surge in its stock price, as reported by S&P Global Market Intelligence.

This spike was catalyzed by a regulatory filing unveiling that Nvidia, a titan in the tech industry, held a stake in Nano-X.

This revelation was perceived as a vote of confidence, propelling the stock upwards. However, the market’s reaction may have been based on a misinterpretation of Nvidia’s involvement.

The Misconception Surrounding Nvidia’s Stake

The narrative that Nvidia’s investment is a direct endorsement of Nano-X’s current operations and future prospects is somewhat misleading.

In reality, Nvidia’s stake in Nano-X is a result of its 2017 investment in Zebra Medical, a venture that Nano-X acquired in 2021 through a stock deal valued at almost $200 million.

Credits: DepositPhotos

Consequently, Nvidia’s possession of nearly 60,000 Nano-X shares is an indirect outcome of its earlier investment, rather than a deliberate move to back Nano-X specifically.

This distinction casts Nvidia’s “stake” in a different light, challenging the assumption of its direct support for Nano-X’s vision and technology.

Nano-X’s Promising Yet Challenging Path

Despite the misconceptions about Nvidia’s involvement, Nano-X’s pursuit to revolutionize the X-ray industry remains undiminished. The company aims to leverage its digital imaging technology to amass a comprehensive database of medical images.

This repository could dramatically enhance patient outcomes through artificial intelligence (AI) algorithms developed by Zebra Medical, which identify early signs of chronic diseases. The potential of integrating AI with a growing image database presents an exciting frontier in medical diagnostics.

Financial and Regulatory Hurdles

Yet, the path to realizing this vision is fraught with financial and regulatory challenges typical of medical start-ups. With only $7.5 million in revenue and a $52 million operating loss reported through the first three quarters of 2023, Nano-X’s financial viability is under scrutiny.

The company is making strides towards commercialization and regulatory approval, having received FDA clearance for its AI software to assess fatty liver images.

These developments are crucial milestones, but Nano-X’s financial health, particularly its cash burn rate and reserves, remains a critical concern for investors.

What Investors Should Watch

As Nano-X prepares to disclose its fourth-quarter financial results for 2023, investors should pay close attention to the company’s financial metrics and management’s outlook for 2024.

The evaluation should not only focus on revenue and losses but also on Nano-X’s strategic initiatives to advance its technology, secure regulatory approvals, and expand its commercial footprint.

Despite the stock’s recent rally and the allure of Nvidia’s indirect stake, Nano-X remains a high-risk investment. However, for those with a long-term perspective, the company’s innovative approach to medical imaging and AI integration holds considerable promise.

A Cautious yet Optimistic Outlook

In conclusion, while the market’s enthusiastic response to Nvidia’s stake in Nano-X may have been premised on a misunderstanding, it has brought significant attention to Nano-X’s innovative endeavors in the medical imaging sector.

Credits: DepositPhotos

Investors considering Nano-X must navigate the excitement with caution, recognizing both the potential and the pitfalls inherent in the company’s journey.

The company’s ambitious goal to disrupt medical imaging with AI-enhanced diagnostics is a compelling narrative, but it is accompanied by substantial financial and regulatory challenges that will test its resilience and ingenuity.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.